(Q44442989)

3 December 2017

1 reference

title

Strategies to optimize adherence to antiretroviral treatment. Interventions in the therapeutic regimen (English)

1 reference

3 December 2017

Hernando Knobel

1

1 reference

PubMed ID

14756993

3 December 2017

Ana Guelar

series ordinal

2

1 reference

PubMed ID

14756993

3 December 2017

language of work or name

Spanish

0 references

publication date

1 February 2004

1 reference

Infectious Diseases and Clinical Microbiology

3 December 2017

1 reference

3 December 2017

22

1 reference

3 December 2017

2

1 reference

3 December 2017

106-112

1 reference

Adherence to protease inhibitor therapy and outcomes in patients with HIV infection

3 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973044-X

7 January 2021

Adherence to triple therapy and viral load response

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973044-X

7 January 2021

A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973044-X

7 January 2021

CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973044-X

7 January 2021

Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973044-X

7 January 2021

The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973044-X

7 January 2021

Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973044-X

7 January 2021

Virologic outcome and predictors of virologic failure of highly active antiretroviral therapy containing protease inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973044-X

7 January 2021

Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973044-X

7 January 2021

Non-adherence to highly active antiretroviral therapy predicts progression to AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973044-X

7 January 2021

Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973044-X

7 January 2021

Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973044-X

7 January 2021

Compliance with zidovudine therapy in patients infected with human immunodeficiency virus, type 1: a cross-sectional study in a municipal hospital clinic

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973044-X

7 January 2021

Addressing the challenges of adherence

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973044-X

7 January 2021

Adherence to antiretroviral and pneumocystis prophylaxis in HIV disease

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973044-X

7 January 2021

Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973044-X

7 January 2021

Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AAC

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973044-X

7 January 2021

Sociodemographic and psychological variables influencing adherence to antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973044-X

7 January 2021

Prospective randomized two-Arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973044-X

7 January 2021

Potential factors affecting adherence with HIV therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973044-X

7 January 2021

Antiretroviral regimen complexity, self-reported adherence, and HIV patients' understanding of their regimens: survey of women in the her study.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973044-X

7 January 2021

Factors affecting adherence to antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973044-X

7 January 2021

A systematic review of the associations between dose regimens and medication compliance

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973044-X

7 January 2021

Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973044-X

7 January 2021

Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973044-X

7 January 2021

Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973044-X

7 January 2021

Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973044-X

7 January 2021

[How and why should adherence to antiretroviral therapy]

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973044-X

7 January 2021

Measurement of Adherence to Antiretroviral Medications

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973044-X

7 January 2021

[Recommendations of the Spanish AIDS Study Group (GESIDA) and the National Aids Plan (PNS) for antiretroviral treatment in adult patients with human immunodeficiency virus infection in 2002].

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973044-X

7 January 2021

Guidelines for using antiretroviral agents among HIV-infected adults and adolescents

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973044-X

7 January 2021

Assessment of readiness to initiate antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973044-X

7 January 2021

Frequency of medical history items, drug interactions, and lifestyle characteristics that may interfere with antiretroviral medications

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973044-X

7 January 2021

Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973044-X

7 January 2021

Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973044-X

7 January 2021

Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973044-X

7 January 2021

Substituting nevirapine for protease inhibitors because of intolerance

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973044-X

7 January 2021

Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973044-X

7 January 2021

Substitution of a nonnucleoside reverse transcriptase inhibitor for a protease inhibitor in the treatment of patients with undetectable plasma human immunodeficiency virus type 1 RNA.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973044-X

7 January 2021

Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973044-X

7 January 2021

Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973044-X

7 January 2021

Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973044-X

7 January 2021

Efavirenz as a substitute for protease inhibitors in HIV-1-infected patients with undetectable plasma viral load on HAART: a median follow-up of 64 weeks.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973044-X

7 January 2021

Switch to efavirenz in a protease inhibitor-containing regimen

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973044-X

7 January 2021

Switching from protease inhibitors to efavirenz: differences in efficacy and tolerance among risk groups: a case-control study from the Swiss HIV Cohort

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973044-X

7 January 2021

Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973044-X

7 January 2021

A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973044-X

7 January 2021

Low risk of treatment failure after substitution of nevirapine for protease inhibitors among human immunodeficiency virus-infected patients with virus suppression

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973044-X

7 January 2021

TRIZAL study: switching from successful HAART to Trizivir (abacavir-lamivudine-zidovudine combination tablet): 48 weeks efficacy, safety and adherence results

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973044-X

7 January 2021

Daily dosing of highly active antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973044-X

7 January 2021

A simple, once-daily dosing regimen for treating HIV-1 infection in intravenous drug users

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973044-X

7 January 2021

Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973044-X

7 January 2021

Once-a-day highly active antiretroviral therapy in treatment-naive HIV-1-infected adults in Senegal

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973044-X

7 January 2021

Different degree of immune recovery using antiretroviral regimens with protease inhibitors or non-nucleosides

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973044-X

7 January 2021

Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973044-X

7 January 2021

Dose-Finding Study of Once-Daily Indinavir/Ritonavir Plus Zidovudine and Lamivudine in HIV-Infected Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973044-X

7 January 2021

A pilot trial of indinavir, ritonavir, didanosine, and lamivudine in a once-daily four-drug regimen for HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973044-X

7 January 2021

Simplifying protease inhibitor therapy with once-daily dosing of saquinavir soft-gelatin capsules/ritonavir (1600/100 mg): HIVNAT 001.3 study

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973044-X

7 January 2021

A pharmacokinetic perspective on medicament noncompliance

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973044-X

7 January 2021

Adherence to antiretroviral therapy among patients with HIV: a critical link between behavioral and biomedical sciences.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973044-X

7 January 2021

Directly observed therapy for the treatment of people with human immunodeficiency virus infection: a work in progress

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973044-X

7 January 2021

Response to lamivudine-zidovudine plus abacavir twice daily in antiretroviral-naive, incarcerated patients with HIV infection taking directly observed treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973044-X

7 January 2021

Interventions to improve adherence to antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973044-X

7 January 2021

Interventions for helping patients to follow prescriptions for medications

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973044-X

7 January 2021

Meta-analysis of trials of interventions to improve medication adherence

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973044-X

7 January 2021

10.1016/S0213-005X(04)73044-X

Identifiers

DOI

1 reference

3 December 2017

1 reference

PubMed ID

14756993